This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tang, W. Articles by Fuchs, S. Y. Search for Related Content PubMed PubMed Citation Articles by Tang, W. Articles by Fuchs, S. Y.

Targeting ß-Transducin Repeat–Containing Protein E3 Ubiquitin Ligase Augments the Effects of Antitumor Drugs on Breast Cancer Cells

Departments of ¹ Animal Biology and ² Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; and ³ Department of Dermatology, University of Wisconsin, Madison, Wisconsin

Requests for reprints: Serge Y. Fuchs, Department of Animal Biology, University of Pennsylvania, 3800 Spruce Street, Room 161E VET, Philadelphia, PA 19104-6046. Phone: 215-573-6949; Fax: 215-573-5188; E-mail: syfuchs{at}vet.upenn.edu.

ß-Transducin repeat–containing proteins (ß-TrCP) serve as substrate recognition component of E3 ubiquitin ligases that control stability of important regulators of cell cycle and signal transduction. ß-TrCP function is essential for the induction of nuclear factor B transcriptional activities, which play a key role in proliferation and survival of cancer cells and are often constitutively up-regulated in human breast cancers. Here we show that inhibition of ß-TrCP either by RNAi approach or by forced expression of a dominant-negative ß-TrCP mutant suppresses growth and survival of human breast cancer cells. In addition, inhibition of ß-TrCP augments the antiproliferative effects of anticancer drugs such as doxorubicin, tamoxifen, and paclitaxel on human mammary tumor cells. These data provide the proof of principle that targeting ß-TrCP might be beneficial for anticancer therapies.

Key Words: ß-TrCP • ubiquitin • E3 ligase • breast cancer • NFB • therapy

This article has been cited by other articles:

				A. Zoubeidi, S. Ettinger, E. Beraldi, B. Hadaschik, A. Zardan, L. W.J. Klomp, C. C. Nelson, P. S. Rennie, and M. E. Gleave Clusterin Facilitates COMMD1 and I-{kappa}B Degradation to Enhance NF-{kappa}B Activity in Prostate Cancer Cells Mol. Cancer Res., January 1, 2010; 8(1): 119 - 130. [Abstract] [Full Text] [PDF]

				A. Plotnikov, B. Varghese, T. H. Tran, C. Liu, H. Rui, and S. Y. Fuchs Impaired Turnover of Prolactin Receptor Contributes to Transformation of Human Breast Cells Cancer Res., April 1, 2009; 69(7): 3165 - 3172. [Abstract] [Full Text] [PDF]

				B. Varghese, H. Barriere, C. J. Carbone, A. Banerjee, G. Swaminathan, A. Plotnikov, P. Xu, J. Peng, V. Goffin, G. L. Lukacs, et al. Polyubiquitination of Prolactin Receptor Stimulates Its Internalization, Postinternalization Sorting, and Degradation via the Lysosomal Pathway Mol. Cell. Biol., September 1, 2008; 28(17): 5275 - 5287. [Abstract] [Full Text] [PDF]

				A. Plotnikov, Y. Li, T. H. Tran, W. Tang, J. P. Palazzo, H. Rui, and S. Y. Fuchs Oncogene-Mediated Inhibition of Glycogen Synthase Kinase 3{beta} Impairs Degradation of Prolactin Receptor Cancer Res., March 1, 2008; 68(5): 1354 - 1361. [Abstract] [Full Text] [PDF]

				Q. Gu, G. T. Bowden, D. Normolle, and Y. Sun SAG/ROC2 E3 ligase regulates skin carcinogenesis by stage-dependent targeting of c-Jun/AP1 and I{kappa}B-{alpha}/NF-{kappa}B J. Cell Biol., September 7, 2007; 178(6): 1009 - 1023. [Abstract] [Full Text] [PDF]

				C. Chen, A. K. Seth, and A. E. Aplin Genetic and Expression Aberrations of E3 Ubiquitin Ligases in Human Breast Cancer Mol. Cancer Res., October 1, 2006; 4(10): 695 - 707. [Abstract] [Full Text] [PDF]